4-(2-氟苯基)-6-甲基-2-哌嗪-1-基噻吩并[2,3-d]嘧啶 | 135991-48-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 中文名称: 4-(2-氟苯基)-6-甲基-2-哌嗪-1-基噻吩并[2,3-d]嘧啶
• 英文名称: MCI-225
• 英文别名: 4-(2-fluorophenyl)-6-methyl-2-piperazinyl-thieno[2,3-d]pyrimidine；4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)thieno[2,3-d]pyrimidine；4-(2-fluoro-phenyl)-6-methyl-2-piperazin-1-yl-thieno[2,3-d]pyrimidine；4-(2-fluorophenyl)-6-methyl-2-piperazinothieno[2,3-d]pyrimidine；DDP-225 free base anhydrous；4-(2-fluorophenyl)-6-methyl-2-piperazin-1-ylthieno[2,3-d]pyrimidine
• CAS: 135991-48-9；99487-25-9
• 化学式: C₁₇H₁₇FN₄S
• 分子量: 328.413
• InChiKey: FVIVKIGLBDRWNR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.5
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.29
• 拓扑面积：
  69.3
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  4-(2-氟苯基)-6-甲基-2-哌嗪-1-基噻吩并[2,3-d]嘧啶 生成 Thieno(2,3-d)pyrimidine, 4-(2-fluorophenyl)-6-methyl-2-(1-piperazinyl)-, monohydrochloride, monohydrate
  参考文献：
  名称：

  Thieno(2,3-d)pyrimidine derivatives and salts thereof

  摘要：

  本发明涉及以下一般式(I)所表示的新型噻唑[2,3-d]嘧啶衍生物或其盐；其中，R1和R2独立地表示氢、卤素或具有1至6个碳原子的烷基；或者R1和R2可以连接形成具有5或6个环碳原子的环烷基；R3和R4独立地表示氢或具有1至6个碳原子的烷基；R5表示从(1)氢或具有1至6个碳原子的烷基，n为1至3的整数，X表示卤素，或者(3)式中，R6表示具有1至6个碳原子的烷基；Ar表示取代或未取代的苯基，或2-或3-噻吩基；n为2或3。本发明的衍生物可用于治疗各种抑郁症或大脑高级功能障碍。

  公开号：

  EP0150469A1
• 作为产物：
  描述：

  2-氯-4-(2-氟苯基)-6-甲基噻吩并[2,3-d]嘧啶 生成 4-(2-氟苯基)-6-甲基-2-哌嗪-1-基噻吩并[2,3-d]嘧啶
  参考文献：
  名称：

  Thieno(2,3-d)pyrimidine derivatives and salts thereof

  摘要：

  本发明涉及以下一般式(I)所表示的新型噻唑[2,3-d]嘧啶衍生物或其盐；其中，R1和R2独立地表示氢、卤素或具有1至6个碳原子的烷基；或者R1和R2可以连接形成具有5或6个环碳原子的环烷基；R3和R4独立地表示氢或具有1至6个碳原子的烷基；R5表示从(1)氢或具有1至6个碳原子的烷基，n为1至3的整数，X表示卤素，或者(3)式中，R6表示具有1至6个碳原子的烷基；Ar表示取代或未取代的苯基，或2-或3-噻吩基；n为2或3。本发明的衍生物可用于治疗各种抑郁症或大脑高级功能障碍。

  公开号：

  EP0150469A1

文献信息

• Thieno(2,3-d)pyrimidine derivatives and salts thereof
  申请人：MITSUBISHI KASEI CORPORATION

  公开号：EP0150469A1

  公开（公告）日：1985-08-07

  This invention relates novel thieno[2,3-d]pyrimidine derivatives represented by the following general formula (I): or salts thereof; wherein R1 and R2 independently represent hydrogen, halogen or alkyl group having 1 to 6 carbon atoms; or R1 and R2 may concatenate to form a cycloalkylene group having 5 or 6 ring carbon atoms; R3 and R4 independently represent hydrogen or alkyl group having 1 to 6 carbon atoms; R5 represents a member selected from (1) hydrogen or alkyl having 1 to 6 carbon atoms, is an integer of from 1 to 3 and X represents halogen, or (3) in which R6 represents alkyl group having 1 to 6 carbon atoms; Ar represents substituted or unsubstituted phenyl, or 2- or 3-thienyl group; and n is 2 or 3. The derivatives of the invention can be used in the treatment of the various depression disease or the higher dysfunction of the brain.

  本发明涉及以下一般式(I)所表示的新型噻唑[2,3-d]嘧啶衍生物或其盐；其中，R1和R2独立地表示氢、卤素或具有1至6个碳原子的烷基；或者R1和R2可以连接形成具有5或6个环碳原子的环烷基；R3和R4独立地表示氢或具有1至6个碳原子的烷基；R5表示从(1)氢或具有1至6个碳原子的烷基，n为1至3的整数，X表示卤素，或者(3)式中，R6表示具有1至6个碳原子的烷基；Ar表示取代或未取代的苯基，或2-或3-噻吩基；n为2或3。本发明的衍生物可用于治疗各种抑郁症或大脑高级功能障碍。
• Soluble salts of thieno[2,3-d]pyrimidine derivatives
  申请人：Cooper Ian Martin

  公开号：US20070254899A1

  公开（公告）日：2007-11-01

  The present invention is directed to novel salts of thieno[2,3-d]pyrimidine derivatives, including 4-(2-fluorophenyl)-6-methyl-2-(piperazin-1-yl)thieno[2,3-d]pyrimidine salts. The present invention is also directed to compositions including such polymorphs and methods for using such salts, e.g., in the treatment of gastrointestinal and/or genitourinary disorders.

  本发明涉及噻唑[2,3-d]嘧啶衍生物的新型盐，包括4-(2-氟苯基)-6-甲基-2-(哌嗪-1-基)噻唑[2,3-d]嘧啶盐。本发明还涉及包含这种多晶体的组合物以及使用这种盐的方法，例如在治疗胃肠和/或泌尿系统疾病中的应用。
• NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION
  申请人：Barlow Carrolee

  公开号：US20070049576A1

  公开（公告）日：2007-03-01

  The instant disclosure describes methods for treating diseases and conditions of the central and peripheral nervous system by stimulating or increasing neurogenesis. The disclosure includes compositions and methods based on muscarinic receptor modulation, such as via inhibition of acetylcholine esterase (AChE) activity, alone or in combination with another neurogenic agent to stimulate or activate the formation of new nerve cells.

  该即时披露描述了通过刺激或增加神经发生来治疗中枢神经系统和外周神经系统的疾病和病症的方法。该披露包括基于毒蕈碱受体调节的组合物和方法，例如通过抑制乙酰胆碱酯酶（AChE）活性，单独或与另一种神经生成剂结合以刺激或激活新神经细胞的形成。
• Method of treating lower urinary tract disorders
  申请人：Dynogen Pharmaceuticals, Inc.

  公开号：EP1795196A2

  公开（公告）日：2007-06-13

  The invention relates to the treatment of at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, and wherein to a subject in need of treatment a therapeutically effective amount of a compound that has 5-HT3 receptor antagonist activity and NorAdrenaline Reuptake Inhibitor (NARI) activity is to be administered. The invention further relates to the treatment of at least one symptom of a lower urinary tract disorder in a subject in need of treatment wherein the symptom is selected from the group consisting of urinary frequency, urinary urgency, urinary urge incontinence, nocturia and enuresis, comprising coadministering to said subject a first amount of a 5HT3 antagonist and a second amount of a NARI, wherein the first and second amounts together comprise a therapeutically effective amount or are each present in a therapeutically effective amount.

  本发明涉及需要治疗的受试者至少一种下尿路疾病症状的治疗，其中该症状选自由尿频、尿急、尿失禁、夜尿和遗尿组成的组，并且对需要治疗的受试者施用治疗有效量的具有5-HT3受体拮抗剂活性和去甲肾上腺素再摄取抑制剂（NARI）活性的化合物。本发明进一步涉及对需要治疗的受试者的至少一种下尿路疾病症状的治疗，其中该症状选自由尿频、尿急、尿失禁、夜尿和遗尿组成的组，包括向所述受试者联合施用第一量的5-HT3受体拮抗剂和第二量的NARI，其中第一量和第二量共同组成治疗有效量或各自以治疗有效量存在。
• Pharmaceutical preparation for the treatment of depressive pathologies, comprising a protein with a high tryptophan/LNAAs (Large Neutral Amino Acids) ratio
  申请人：Kolfarma S.r.L.

  公开号：EP2218462A1

  公开（公告）日：2010-08-18

  A pharmaceutical preparation including at least one selective serotonin re-uptake inhibitor (SSRI) or selective serotonin and noradrenaline re-uptake inhibitor (SSNRI) and a protein with a high tryptophan/LNAAs ratio, preferably α-lactalbumin, is described; the preparation may consist of a pharmaceutical composition containing both of the active ingredients or of distinct dosage units separately containing the above-stated active ingredients and is used in the treatment of depressive pathologies.

  描述了一种药物制剂，其中包括至少一种选择性 5-羟色胺再摄取抑制剂（SSRI）或选择性 5-羟色胺和去甲肾上腺素再摄取抑制剂（SSNRI）以及一种色氨酸/去甲肾上腺素比例较高的蛋白质，优选α-乳白蛋白；该制剂可以由含有两种活性成分的药物组合物组成，也可以由分别含有上述活性成分的不同剂量单位组成，用于治疗抑郁症。